The compound you described, **1-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-3-(4-methylphenyl)sulfonylurea**, is a synthetic molecule. It's not a naturally occurring compound and there's limited information available about its specific properties and potential uses.
However, based on its structure, we can make some inferences:
* **Sulfonylurea moiety:** The presence of the sulfonylurea group (-SO2NHCONH2) is significant. This functional group is known to occur in various pharmaceuticals, including:
* **Antidiabetic drugs:** Sulfonylureas like glibenclamide and glipizide are widely used to treat type 2 diabetes by stimulating insulin secretion from pancreatic beta cells.
* **Herbicides:** Sulfonylureas like chlorsulfuron and triflusulfuron are potent herbicides that inhibit acetolactate synthase, an enzyme crucial for plant growth.
* **Pyrazole ring:** The presence of a pyrazole ring (a five-membered heterocyclic ring containing two nitrogen atoms) suggests potential for activity in various pharmacological areas. Pyrazoles are found in various drugs, including anti-inflammatory agents, analgesics, and anti-cancer drugs.
**Why it might be important for research:**
* **Potential as a drug lead:** The combination of the sulfonylurea group and the pyrazole ring suggests that this compound might exhibit pharmacological activity. Further research could investigate its potential as a drug candidate for various diseases, including diabetes, cancer, or inflammatory conditions.
* **Structure-activity relationship (SAR) studies:** This compound could serve as a starting point for exploring structure-activity relationships. By modifying different parts of the molecule, researchers could investigate how changes in structure affect the compound's activity and optimize its properties.
* **Synthesis and medicinal chemistry:** The synthesis of this compound would provide a platform for exploring novel synthetic strategies and understanding the chemistry of this complex molecule.
**To understand its importance for research fully, more specific information is needed, including:**
* **Its biological activity:** Does it show any activity in vitro or in vivo?
* **Its pharmacological profile:** Does it target specific pathways or enzymes?
* **Its safety profile:** Is it toxic or does it have undesirable side effects?
Without this information, it's impossible to determine its significance for research without further investigation.
ID Source | ID |
---|---|
PubMed CID | 1241123 |
CHEMBL ID | 1346629 |
CHEBI ID | 120822 |
SCHEMBL ID | 6466850 |
Synonym |
---|
3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1h-pyrazol-4-yl)-1-(4-methylbenzenesulfonyl)urea |
MLS000048625 |
smr000060857 |
OPREA1_293114 |
SR-01000604821-2 |
OPREA1_424011 |
CHEBI:120822 |
AKOS003624594 |
HMS2480M17 |
1-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-(4-methylphenyl)sulfonylurea |
((2,3-dimethyl-5-oxo-1-phenyl(3-pyrazolin-4-yl))amino)-n-((4-methylphenyl)sulfonyl)formamide |
CCG-50967 |
STL477386 |
n-[(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1h-pyrazol-4-yl)carbamoyl]-4-methylbenzenesulfonamide |
MS-8317 |
326015-55-8 |
CHEMBL1346629 |
SCHEMBL6466850 |
Q27208965 |
1-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-3-(4-methylphenyl)sulfonylurea |
mfcd00247400 |
Z44583975 |
Class | Description |
---|---|
ring assembly | Two or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved. |
pyrazoles | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 3.1623 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
GLS protein | Homo sapiens (human) | Potency | 31.6228 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 15.7279 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |